Michelle Lockley's Avatar

Michelle Lockley

@mlockley.bsky.social

Medical oncologist and scientist, into all things ovarian cancer. In search of the answer to cancer drug resistance

491 Followers  |  423 Following  |  3 Posts  |  Joined: 10.10.2023  |  1.5699

Latest posts by mlockley.bsky.social on Bluesky

Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control Abstract. Drug resistance results in poor outcomes for cancer patients. Adaptive therapy is a potential strategy to address drug resistance that exploits competitive interactions between sensitive and...

Oops, here you go: aacrjournals.org/cancerres/ar...

02.05.2025 13:14 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control Abstract. Drug resistance results in poor outcomes for cancer patients. Adaptive therapy is a potential strategy to address drug resistance that exploits competitive interactions between sensitive and...

With the brilliant @mlockley.bsky.social we've been exploring chemo resistance evolution in ovarian cancer. We find resistance has a fitness cost which means resistant cells are outcompeted by sensitive cells when treatment is stopped.
aacrjournals.org/cancerres/ar...

@icr.ac.uk @qmbci.bsky.social

02.05.2025 12:43 β€” πŸ‘ 36    πŸ” 6    πŸ’¬ 2    πŸ“Œ 0
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on cha... Introduction Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relaps...

This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...

02.05.2025 12:50 β€” πŸ‘ 4    πŸ” 2    πŸ’¬ 1    πŸ“Œ 0
Preview
Smarter chemotherapy approach could delay drug resistance in ovarian cancer - Barts Cancer Institute - Queen Mary University of London Adaptive chemotherapy can prolong survival in lab models of ovarian cancer, according to new results. The findings could pave the way for a more effective and gentler approach to treating ovarian canc...

πŸ“° Can we use the power of evolution to improve ovarian cancer survival?

A surprising approach called adaptive therapy holds promise, according to findings by @mlockley.bsky.social & team at @qmul.ac.uk & @icr.ac.uk.

Read more ➑️ www.bci.qmul.ac.uk/general-news...

#AACR25 #medsky #oncoskyπŸ§ͺ

30.04.2025 12:10 β€” πŸ‘ 19    πŸ” 7    πŸ’¬ 3    πŸ“Œ 0

Can we use the power of evolution to improve ovarian cancer treatment? Our latest paper says yes! Online now at Cancer Research. Thanks to
@trevorgraham.bsky.social coauthors and @cancerresearchuk.org for funding.

30.04.2025 13:19 β€” πŸ‘ 9    πŸ” 3    πŸ’¬ 1    πŸ“Œ 0
Post image

Delighted to speak at Moffitt Cancer centre last week. Great to share our research and really enjoyed the thought provoking discussions. Many thanks to Joel brown for hosting

28.05.2024 08:02 β€” πŸ‘ 4    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

@mlockley is following 20 prominent accounts